The Mortality and Its Associated Factors in Schizophrenia Patients Older Than 60 Years
试验速览
- 阶段
- 不适用
- 发起方
- CHU de Reims
- 入组人数
- 685
- 试验地点
- 1
- 主要终点
- Death
研究概览
简要总结
As in the general population, there is a gradual and steady increase in life expectancy of patients with schizophrenia. But this increase is at a smaller scale, with a rate of premature death that is still 2 to 3 times higher than that found in the general population. This excessive early mortality is explained by an overrepresentation of suicide deaths, but also a higher prevalence of somatic diseases, mainly cardiovascular. But today there are only very few epidemiological data on the mortality of patients with schizophrenia, including those aged over 60 years. What are the sociodemographic and clinical characteristics (psychiatric and somatic) of these schizophrenic elderly patients? Do they benefit from a somatic follow-up adequate and systematic? What are their levels of social independence and of quality of life? the answers these questions and the description of the offer of geriatric care and of psychiatric care currently provided by different sectors of psychiatry in France is an indispensable prerequisite for any project to improve the quality of life, state of health and mortality of older patients with schizophrenia.
详细描述
Evaluate prospectively over 5 years, the rates and causes of mortality in a cohort of schizophrenic patients older than 60 years, followed by adult psychiatry sectors, compared to those patients matched for sex and age and monitored by the same sectors for a chronic psychiatric disorder other than schizophrenia
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 60 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women aged than 60 years with a diagnosis of schizophrenia, according to the DSM-IV criteria
- •Men or women aged than 60 years with chronic psychiatric disorder other than schizophrenia
- •Patients consenting to participate to the study
- •Patients enrolled in the national healthcare insurance program
排除标准
- •Disease affecting the central nervous system
结局指标
主要结局
Death
时间窗: 5 years
Death of any causes
次要结局
未报告次要终点
